Argenx gears up to launch Vyvgart in next potential indication
ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patients able to significantly reduce steroid use over first...
RHO study supports proof-of-concept in primary Sjogren's disease Decision informed by favorable safety profile and consistency across efficacy and biomarker measures March 27, 2024, 7:00...
argenx Announces Approval of VYVGART in Japan for immune Thrombocytopenia
Argenx is laying the groundwork for the anticipated expansion of its flagship drug into a new indication, kicking off the unbranded “Shining Through CIDP” campaign ahead of a potential FDA approval in June.
The unbranded “Shining through CIDP” campaign showcases real stories of caregivers and people living with chronic inflammatory demyelinating polyradiculoneuropathy, similar to its 2020 “MG United” campaign and docuseries about myasthenia gravis.
February 26, 2024Amsterdam, the Netherlands argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
February 22, 2024Amsterdam, the Netherlands argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
Prescription Drug User Fee Act (PDUFA) target action date is June 21, 2024 If approved, VYVGART® Hytrulo will be the first neonatal Fc receptor (FcRn) blocker to treat CIDP February 20, 2024, 7:00...